# A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy

> **NCT01419197** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 602 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Trastuzumab emtansine
- **DRUG:** Treatment of physician's choice

## Key facts

- **NCT ID:** NCT01419197
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2013-02
- **Final completion:** 2015-08
- **Target enrollment:** 602 (ACTUAL)
- **Last updated:** 2016-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01419197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01419197, "A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01419197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*